• Peace of mind for the concerned consumer

    Anatara plans to develop Detach for use in farmed animals, providing an alternative to the use of antibiotics and thereby helping farmers supply antibiotic free meat.

  • Natural treatment for animal health

    Anatara’s Detach™ is a proven natural non-antibiotic treatment for diarrhoea in piglets with the potential for use in other farm livestock. More »

  • Advancing gastrointestinal health naturally

    Our product is made using an extract from pineapple stems that blocks the causes of diarrhoea. It’s a natural product that won’t contribute to the rise of so-called “superbugs” caused by the overuse of antibiotics.

Company description

Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Video overview

Latest news All news

  • Anatara receives second Zoetis payment

    Anatara Lifesciences is pleased to announce that it has received a second payment under the exclusive Research Evaluation and License Option Agreement with the global animal health company, Zoetis Inc., to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals.

    Please click here to view the ASX announcement.

  • NDF Research Research & Valuation Report

    NDF Research’s Initiation of Coverage Research & Valuation Report

    NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.

    Please click here to view the report.

Investors

Investors Home

Pause